Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sara Galimberti

Showing results (51-60 of 313) with videos related to

Pageof 32
Sort By:
Leukemia Research|September 27, 2005
Chronic myeloid leukaemia and hairy cell leukaemia coexisting in a single patient: difficulties at diagnosis and rational of the therapeutic strategyEnrico Orciuolo, Rita Fazzi, Sara Galimberti, et al.
Leukemia Research|July 20, 2002
Bone and bone marrow interactions: hematological activity of osteoblastic growth peptide (OGP)-derived carboxy-terminal pentapeptide. II. Action on human hematopoietic stem cellsRita Fazzi, Sara Galimberti, Rossana Testi, et al.
American Journal of Hematology|August 19, 2011
High-dose (40,000 IU twice/week) alpha recombinant human erythropoietin as single agent in low/intermediate risk myelodysplastic syndromes: a retrospective investigation on 133 patients treated in a single institutionAntonio Azzarà, Giovanni Carulli, Sara Galimberti, et al.
Hematology Reports|January 16, 2018
PRDI-BF1 and PRDI-BF1P isoform expressions correlate with disease status in multiple myeloma patientsGabriele Buda, Francesca Guerrini, Sara Galimberti, et al.
Leukemia Research|May 6, 2009
2CdA chemotherapy and rituximab in the treatment of marginal zone lymphomaEnrico Orciuolo, Gabriele Buda, Elisabetta Sordi, et al.
Leukemia Research|April 10, 2007
Complex translocation t(6;9;22)(p21.1;q34;q11) at diagnosis is a therapy resistance index in chronic myeloid leukaemiaEnrico Orciuolo, Gabriele Buda, Sara Galimberti, et al.
TH Open : Companion Journal to Thrombosis and Haemostasis|June 29, 2019
Interference of Monoclonal Gammopathy with Fibrinogen Assay Producing Spurious DysfibrinogenemiaFrancesca Martini, Nadia Cecconi, Aldo Paolicchi, et al.
British Journal of Haematology|August 20, 2008
Rituximab as treatment for minimal residual disease in hairy cell leukaemia: extended follow-upGiulia Cervetti, Sara Galimberti, Francesca Andreazzoli, et al.
Gynecologic Oncology|October 27, 2007
Unusual association of endometrial cancer and multiple myelomaGabriele Buda, Enrico Orciuolo, Sara Galimberti, et al.
Leukemia Research|August 31, 2007
MDR1 pump: more than a drug transporter comment on "Regulatory polymorphisms of multidrug resistance 1 (MDR1) gene are associated with the development of childhood acute lymphoblastic leukaemia" by Hattori et al. [Leuk. Res. (in press)]Gabriele Buda, Enrico Orciuolo, Valentina Maggini, et al.
Pageof 32

Showing results (51-60 of 313) with videos related to

Sort By:
Pageof 32
Leukemia Research|September 27, 2005
Chronic myeloid leukaemia and hairy cell leukaemia coexisting in a single patient: difficulties at diagnosis and rational of the therapeutic strategyEnrico Orciuolo, Rita Fazzi, Sara Galimberti, et al.
Leukemia Research|July 20, 2002
Bone and bone marrow interactions: hematological activity of osteoblastic growth peptide (OGP)-derived carboxy-terminal pentapeptide. II. Action on human hematopoietic stem cellsRita Fazzi, Sara Galimberti, Rossana Testi, et al.
American Journal of Hematology|August 19, 2011
High-dose (40,000 IU twice/week) alpha recombinant human erythropoietin as single agent in low/intermediate risk myelodysplastic syndromes: a retrospective investigation on 133 patients treated in a single institutionAntonio Azzarà, Giovanni Carulli, Sara Galimberti, et al.
Hematology Reports|January 16, 2018
PRDI-BF1 and PRDI-BF1P isoform expressions correlate with disease status in multiple myeloma patientsGabriele Buda, Francesca Guerrini, Sara Galimberti, et al.
Leukemia Research|May 6, 2009
2CdA chemotherapy and rituximab in the treatment of marginal zone lymphomaEnrico Orciuolo, Gabriele Buda, Elisabetta Sordi, et al.
Leukemia Research|April 10, 2007
Complex translocation t(6;9;22)(p21.1;q34;q11) at diagnosis is a therapy resistance index in chronic myeloid leukaemiaEnrico Orciuolo, Gabriele Buda, Sara Galimberti, et al.
TH Open : Companion Journal to Thrombosis and Haemostasis|June 29, 2019
Interference of Monoclonal Gammopathy with Fibrinogen Assay Producing Spurious DysfibrinogenemiaFrancesca Martini, Nadia Cecconi, Aldo Paolicchi, et al.
British Journal of Haematology|August 20, 2008
Rituximab as treatment for minimal residual disease in hairy cell leukaemia: extended follow-upGiulia Cervetti, Sara Galimberti, Francesca Andreazzoli, et al.
Gynecologic Oncology|October 27, 2007
Unusual association of endometrial cancer and multiple myelomaGabriele Buda, Enrico Orciuolo, Sara Galimberti, et al.
Leukemia Research|August 31, 2007
MDR1 pump: more than a drug transporter comment on "Regulatory polymorphisms of multidrug resistance 1 (MDR1) gene are associated with the development of childhood acute lymphoblastic leukaemia" by Hattori et al. [Leuk. Res. (in press)]Gabriele Buda, Enrico Orciuolo, Valentina Maggini, et al.
Pageof 32